New YorkLimits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology
What it does
Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed 1st Chamber
- Passed 2nd Chamber
- To Governor
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2026
- Jan 7REFERRED TO HEALTHLatest
- 2025
- Jan 8REFERRED TO HEALTHIntroduced